Tags

Type your tag names separated by a space and hit enter

Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib.
Leuk Res. 2009 Jan; 33(1):174-7.LR

Abstract

Prognosis of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation (SCT) is dismal. Immunotherapy with donor lymphocyte infusion (DLI) and imatinib are rarely and/or transiently effective. Here we describe the case of a patient with imatinib-resistant post-transplant relapse of ALL, who received a combination of standard dose nilotinib and monthly DLI infusion. Therapy was well tolerated and the patient achieved and maintained a complete molecular remission. Our case provides a rationale for the combined use of a second line tyrosine kinase inhibitor and DLI in the treatment of relapsed Ph+ ALL.

Authors+Show Affiliations

Division of Hematology and Bone Marrow Transplantation, Department of Medical and Morphological Researches, Azienda Ospedaliero-Universitaria, P.zzale S. M. Misericordia, 15, 33100 Udine, Italy. mario.tiribelli@uniud.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

18471874

Citation

Tiribelli, Mario, et al. "Nilotinib and Donor Lymphocyte Infusion in the Treatment of Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ ALL) Relapsing After Allogeneic Stem Cell Transplantation and Resistant to Imatinib." Leukemia Research, vol. 33, no. 1, 2009, pp. 174-7.
Tiribelli M, Sperotto A, Candoni A, et al. Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leuk Res. 2009;33(1):174-7.
Tiribelli, M., Sperotto, A., Candoni, A., Simeone, E., Buttignol, S., & Fanin, R. (2009). Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leukemia Research, 33(1), 174-7. https://doi.org/10.1016/j.leukres.2008.03.031
Tiribelli M, et al. Nilotinib and Donor Lymphocyte Infusion in the Treatment of Philadelphia-positive Acute Lymphoblastic Leukemia (Ph+ ALL) Relapsing After Allogeneic Stem Cell Transplantation and Resistant to Imatinib. Leuk Res. 2009;33(1):174-7. PubMed PMID: 18471874.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. AU - Tiribelli,Mario, AU - Sperotto,Alessandra, AU - Candoni,Anna, AU - Simeone,Erica, AU - Buttignol,Silvia, AU - Fanin,Renato, Y1 - 2008/05/08/ PY - 2008/02/14/received PY - 2008/03/27/revised PY - 2008/03/27/accepted PY - 2008/5/13/pubmed PY - 2009/1/3/medline PY - 2008/5/13/entrez SP - 174 EP - 7 JF - Leukemia research JO - Leuk Res VL - 33 IS - 1 N2 - Prognosis of patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation (SCT) is dismal. Immunotherapy with donor lymphocyte infusion (DLI) and imatinib are rarely and/or transiently effective. Here we describe the case of a patient with imatinib-resistant post-transplant relapse of ALL, who received a combination of standard dose nilotinib and monthly DLI infusion. Therapy was well tolerated and the patient achieved and maintained a complete molecular remission. Our case provides a rationale for the combined use of a second line tyrosine kinase inhibitor and DLI in the treatment of relapsed Ph+ ALL. SN - 0145-2126 UR - https://www.unboundmedicine.com/medline/citation/18471874/Nilotinib_and_donor_lymphocyte_infusion_in_the_treatment_of_Philadelphia_positive_acute_lymphoblastic_leukemia__Ph+_ALL__relapsing_after_allogeneic_stem_cell_transplantation_and_resistant_to_imatinib_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0145-2126(08)00174-4 DB - PRIME DP - Unbound Medicine ER -